Adrenoceptor
Jan 04, 2007 at 13:48 | Source:
Photos »
/ 
Related News »
In phase II results presented here yesterday, the investigational beta3-adrenoceptor agonist solabegron yielded statistically significant improvements in symptoms of overactive bladder compared to placebo and was safe and well tolerated ...
May 21, 2012 at 00:45 | Source: ModernMedicine
Solabegron produced statistically significant improvements in symptoms of overactive bladder (OAB) compared to placebo and was safe and well-tolerated Solabegron, a novel beta3-adrenoceptor agonist with high affinity and selectivity, is also in clinical ...
May 21, 2012 at 13:38 | Source: Business Wire
Solabegron is a highly selective high-affinity beta-3 adrenoceptor agonist currently in clinical development for the treatment of OAB symptoms. In the study, 258 women with OAB symptoms (at least 8 micturitions, at least 1 incontinence episode, and at ...
May 23, 2012 at 17:32 | Source: Medscape News
Solabegron is a novel beta3-adrenoceptor agonist with high affinity and selectivity that is in late stage clinical development for the treatment of OAB and irritable bowel syndrome (IBS). “The results are encouraging, particularly for patients ...
May 21, 2012 at 14:57 | Source: News-Medical.Net
For example, in 2007, de Quervain and his colleagues showed that a variant of the α2B adrenoceptor is also linked to enhanced formation of emotional and traumatic memories in both healthy Europeans and survivors of the Rwandan civil war, but it was not ...
May 14, 2012 at 21:03 | Source: Nature.com